

In the Claims:

Please amend the claims as follows:

{ Please add new claims 19-48, as follows: }

Sul
113

19. (New) A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a TR11 polypeptide selected from the group consisting of:

(a) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of SEQ ID NO:2;

(b) a polypeptide whose amino acid sequence comprises amino acid residues 26-162 of SEQ ID NO:2;

A1

(c) a polypeptide whose amino acid sequence comprises amino acid residues 26-139 of SEQ ID NO:2;

[scribble]

(d) a polypeptide whose amino acid sequence comprises amino acid residues 1-164 of SEQ ID NO:2;

(e) a polypeptide whose amino acid sequence comprises amino acid residues 46-164 of SEQ ID NO:2;

(f) a polypeptide whose amino acid sequence comprises amino acid residues 33-154 of SEQ ID NO:2;

(g) a polypeptide whose amino acid sequence comprises amino acid residues 33-73 of SEQ ID NO:2;

(h) a polypeptide whose amino acid sequence comprises amino acid residues 74-113 of SEQ ID NO:2; and

[signature]

(i) a polypeptide whose amino acid sequence comprises amino acid residues 114 to 154 of SEQ ID NO:2;
in a pharmaceutically acceptable carrier.

~~20.~~ (New) The method of claim ~~19~~ wherein the mammal is a human.

~~21.~~ (New) The method of claim ~~19~~ wherein the TR11 polypeptide is fused to a heterologous polypeptide.

~~22.~~ (New) The method of claim ~~21~~ wherein the heterologous polypeptide is an immunoglobulin constant domain.

~~23.~~ (New) The method of claim ~~22~~ wherein the immunoglobulin constant domain is an IgG1 constant domain.

~~24.~~ (New) The method of claim ~~22~~ wherein the immunoglobulin constant domain is an IgG3 constant domain.

~~25.~~ (New) The method of claim ~~24~~ wherein the heterologous polypeptide is human albumin.

~~26.~~ (New) The method of claim ~~25~~ wherein the pharmaceutically acceptable carrier is water.

9
~~27.~~ (New) The method of claim ~~19~~ wherein the pharmaceutically acceptable carrier is saline.

10
~~28.~~ (New) The method of claim ~~19~~ wherein the pharmaceutically acceptable carrier is Ringer's solution.

11
~~29.~~ (New) The method of claim ~~19~~ wherein the pharmaceutically acceptable carrier is dextrose solution.

12
~~30.~~ (New) The method of claim ~~19~~ wherein the pharmaceutically acceptable carrier is ethyl oleate.

A1
uf 13
~~31.~~ (New) The method of claim ~~19~~ wherein the pharmaceutically acceptable carrier is a liposome.

14
~~32.~~ (New) The method of claim ~~19~~ wherein the TR11 polypeptide inhibits T cell migration across endothelial cells.

Sub
C14 33. (New) A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a TR11 polypeptide selected from the group consisting of:

- (a) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (b) a polypeptide whose amino acid sequence comprises amino acid residues 26-162 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (c) a polypeptide whose amino acid sequence comprises amino acid residues 26-139 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (d) a polypeptide whose amino acid sequence comprises amino acid residues 1-164 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (e) a polypeptide whose amino acid sequence comprises amino acid residues 46-164 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (f) a polypeptide whose amino acid sequence comprises amino acid residues 33-154 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (g) a polypeptide whose amino acid sequence comprises amino acid residues 33-73 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- (h) a polypeptide whose amino acid sequence comprises amino acid residues 74-113 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340; and
- (i) a polypeptide whose amino acid sequence comprises amino acid residues 114 to 154 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209340;
- in a pharmaceutically acceptable carrier.

(New) The method of claim 35 wherein the mammal is a human.

~~35~~
36. (New) The method of claim 35 wherein the TR11 polypeptide is fused to a heterologous polypeptide.

~~36~~
37. (New) The method of claim 36 wherein the heterologous polypeptide is an immunoglobulin constant domain.

Handwritten: 124 w/
~~37~~
38. (New) The method of claim 37 wherein the immunoglobulin constant domain is an IgG1 constant domain.

Handwritten: 124 w/
~~38~~
39. (New) The method of claim 37 wherein the immunoglobulin constant domain is an IgG3 constant domain.

Handwritten: 124 w/
~~39~~
40. (New) The method of claim 36 wherein the heterologous polypeptide is human albumin.

~~40~~
41. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is water.

~~41~~
42. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is saline.

~~42~~
43. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is Ringer's solution.

43
44. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is dextrose solution.

44
45. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is ethyl oleate.

45
46. (New) The method of claim 35 wherein the pharmaceutically acceptable carrier is a liposome.

46
47. (New) The method of claim 35 wherein the TR11 polypeptide inhibits T cell migration across endothelial cells.

47
48 (New) A method of inhibiting binding of Endokine-alpha to endogenous Endokine-alpha receptors in a mammal comprising administering to said mammal an effective amount of a polypeptide selected from the group consisting of:

(a) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of SEQ ID NO:4;

(b) a polypeptide whose amino acid sequence comprises amino acid residues 1-162 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(c) a polypeptide whose amino acid sequence comprises amino acid residues 1-168 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209341;

(d) a polypeptide whose amino acid sequence comprises amino acid residues 20-168 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209342;

(e) a polypeptide whose amino acid sequence comprises amino acid residues 1-168 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209342; and

(f) a polypeptide whose amino acid sequence comprises amino acid residues 20-168 of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 209342; in a pharmaceutically acceptable carrier.